ABSTRACT
AIM:
To observe the
efficacy of intravitreal conbercept
injection for chronic
central serous chorioretinopathy (CSC).
METHODS:
Nine
eyes of 9
patients diagnosed as chronic CSC between October 2015 to May 2016 were treated with an
intravitreal injection of conbercept (0.5mg/0.05mL) (six
patients were given the same does of
intravitreal injection again at 1mo after the first
injection).Follow-up
observation was at 1, 2, and 6mo after
injection.Observed
indicators included best-corrected
visual acuity (BCVA),
intraocular pressure,
optical coherence tomography (OCT), fundus
fluorescein angiography (FFA), choroidal
indocyanine green angiography (ICGA), macular fovea thickness (CMT), subfoveal choroidal thickness (SFCT).
RESULTS:
Seven of the 9
patients responded significantly to the
drug, while 2
patients had no response.The CMT was 373.12±72.43μm at baseline, which decreased significantly to 332.05±67.13μm, 282.24±62.30μm and 225.56±71.08μm at 1, 2 and 6mo after the
intravitreal injection.The mean thickness of SFCT was 422.11±64.82μm before
treatment.The choroidal thickness of non-responsive
patients before
treatment was below average, respectively 353μm and 365μm.The SFCT of 1, 2, and 6mo
after treatment was 391.45±75.24μm, 365.53±63.07μm, 355.40±66.65μm.Before
treatment and 1mo after, there was no significant difference (P=0.074), but there was statistically significant (P0.05).
CONCLUSION:
Intravitreal conbercept
injection in chronic CSC may have some effect in accelerating subertinal fluid resolution and decreasing the CMT.The SFCT within 6mo
after treatment was significantly lower than pretreatment.The SFCT may be an
indicator of whether
patients respond.